biotech

Italian drugmaker Chiesi will pay $27 a share for KalVista Pharmaceuticals to acquire Ekterly, the first oral on-demand treatment for hereditary angioedema, in a deal expected to close in the third quarter.

The FDA announced two proof-of-concept real-time cancer trials and opened public comment on a broader pilot program, betting that cloud and AI-mediated data flow can compress drug review timelines.

Eli Lilly's deal with Bezos-backed Profluent funds AI-designed recombinases that aim to insert entire genes, going beyond CRISPR's localized cuts.

Regeneron's one-time intracochlear gene therapy for OTOF-related deafness cleared the FDA 61 days after BLA filing, the first gene therapy product approved under the Commissioner's National Priority Voucher pilot program.

Intellia Therapeutics will report topline Phase 3 results for lonvoguran ziclumeran in hereditary angioedema on April 27, 2026 — the first Phase 3 readout for any in vivo CRISPR candidate.

OpenAI's first domain-specific model for biology and drug discovery connects to 50+ scientific databases and outperformed human experts on RNA sequence tasks, but faces established rivals and a decade-long clinical validation gap.

QUT and Baker-lab researchers built AI-designed allosteric switches that turn on in the presence of small molecules, peptides, or whole proteins and work inside bacteria or on electrodes.

Phase 3 data presented at AAN 2026 show azetukalner nearly halved seizure frequency in treatment-resistant focal epilepsy, with 38% of long-term patients achieving over a year of seizure freedom.

Early-phase data in 81 children with Dravet syndrome showed large seizure reductions and manageable safety issues as a phase 3 trial moves ahead.

Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.

UT Austin and Metagenomi researchers engineered Al3Cas12f RKK, a compact CRISPR enzyme that achieves over 80% editing efficiency while fitting inside AAV delivery vehicles.

Prime Medicine is pursuing accelerated approval for PM359, an autologous prime editing therapy that restored immune function in both patients treated for chronic granulomatous disease, marking the first clinical use of prime editing technology.